**Core Concept**
Surgery is often the primary treatment for localized renal cell carcinoma (RCC), but for patients with surgically unresectable disease, targeted therapy becomes a crucial option. The goal is to slow disease progression and manage symptoms. The correct choice should be a drug that has shown efficacy in treating advanced RCC.

**Why the Correct Answer is Right**
Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that has demonstrated significant clinical activity in patients with advanced RCC. It works by inhibiting the activity of certain enzymes, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT. By blocking these pathways, sunitinib reduces tumor growth, angiogenesis, and metastasis. This mechanism of action makes sunitinib an effective treatment for patients with surgically unresectable RCC.

**Why Each Wrong Option is Incorrect**
**Option A:** Sorafenib is another RTK inhibitor used in the treatment of advanced RCC, but it is not the first choice for surgically unresectable disease.
**Option C:** Imatinib is primarily used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), not RCC.
**Option D:** Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used in the treatment of colorectal and head and neck cancers, but not RCC.

**Clinical Pearl / High-Yield Fact**
For patients with advanced RCC, it's essential to consider the potential side effects of targeted therapy, including hypertension, fatigue, and diarrhea. Regular monitoring and dose adjustments can help minimize these effects and optimize treatment outcomes.

**✓ Correct Answer: B. Sunitinib**